Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501
Mar 27, 2017 11:35 am UTC| Business
- Oral administration of MAT2501 at all tested doses yielded blood levels that were well below the labeled safety limits recommended for IV-administered amikacin - - MAT2501 was well-tolerated with no serious adverse...
Next Generation Sequencing Market, 2022
Mar 27, 2017 11:34 am UTC| Business
Dublin, March 27, 2017 -- Research and Markets has announced the addition of the "Next Generation Sequencing Global market - Forecast to 2022" report to their offering. The global...
Mar 27, 2017 11:34 am UTC| Business
DUBLIN, Ireland and BOSTON, March 27, 2017 -- Allergan plc, (NYSE:AGN), a leading global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and...
VBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial Results
Mar 27, 2017 11:34 am UTC| Business
Interim analysis in the GLOBE pivotal study is expected in mid-2017, with top-line data expected in early 2018Phase 3 Study of VB-111 in Ovarian Cancer Currently Expected to Begin Enrollment in the Second Half of 2017 TEL...
Strongbridge Biopharma plc Provides Corporate Update and Reports Full-Year 2016 Financial Results
Mar 27, 2017 11:33 am UTC| Business
DUBLIN, Ireland and TREVOSE, Pa., March 27, 2017 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare...
KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum
Mar 27, 2017 11:32 am UTC| Business
CORALVILLE, Iowa, March 27, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett,...
Conatus to Present at Upcoming Investor Conferences
Mar 27, 2017 11:31 am UTC| Business
SAN DIEGO, March 27, 2017 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company’s scheduled presentations at two upcoming investor conferences in New York: H.C. Wainwright NASH Investor Conference...